BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30214897)

  • 1. Encapsulation of the HSP-90 Chaperone Inhibitor 17-AAG in Stable Liposome Allow Increasing the Therapeutic Index as Assessed,
    Petersen ALOA; Campos TA; Dantas DADS; Rebouças JS; da Silva JC; de Menezes JPB; Formiga FR; de Melo JV; Machado G; Veras PST
    Front Cell Infect Microbiol; 2018; 8():303. PubMed ID: 30214897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17-AAG kills intracellular Leishmania amazonensis while reducing inflammatory responses in infected macrophages.
    Petersen AL; Guedes CE; Versoza CL; Lima JG; de Freitas LA; Borges VM; Veras PS
    PLoS One; 2012; 7(11):e49496. PubMed ID: 23152914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid lipid nanoparticles as a novel formulation approach for tanespimycin (17-AAG) against leishmania infections: Preparation, characterization and macrophage uptake.
    Pires VC; Magalhães CP; Ferrante M; Rebouças JS; Nguewa P; Severino P; Barral A; Veras PST; Formiga FR
    Acta Trop; 2020 Nov; 211():105595. PubMed ID: 32585150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapeutic potential of 17-AAG against cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
    Santos DM; Petersen AL; Celes FS; Borges VM; Veras PS; de Oliveira CI
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3275. PubMed ID: 25340794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of the anti-leishmanial activity and toxicity of PK11195.
    Guedes CES; Dias BRS; Petersen ALOA; Cruz KP; Almeida NJ; Andrade DR; Menezes JPB; Borges VM; Veras PST
    Mem Inst Oswaldo Cruz; 2018 Feb; 113(4):e170345. PubMed ID: 29412342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
    Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
    Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticles Loaded with a New Thiourea Derivative: Development and
    Meireles PW; de Souza DPB; Rezende MG; Borsodi MPG; de Oliveira DE; da Silva LCRP; de Souza AMT; Viana GM; Rodrigues CR; do Carmo FA; de Sousa VP; Rossi-Bergmann B; Cabral LM
    Curr Drug Deliv; 2020; 17(8):694-702. PubMed ID: 32621717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
    Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
    Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme.
    Saxena V; Hussain MD
    Colloids Surf B Biointerfaces; 2013 Dec; 112():350-5. PubMed ID: 24012704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A lupane-triterpene isolated from Combretum leprosum Mart. fruit extracts that interferes with the intracellular development of Leishmania (L.) amazonensis in vitro.
    Teles CB; Moreira-Dill LS; Silva Ade A; Facundo VA; de Azevedo WF; da Silva LH; Motta MC; Stábeli RG; Silva-Jardim I
    BMC Complement Altern Med; 2015 Jun; 15():165. PubMed ID: 26048712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
    Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
    Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imipramine alters the sterol profile in Leishmania amazonensis and increases its sensitivity to miconazole.
    Andrade-Neto VV; Pereira TM; Canto-Cavalheiro Md; Torres-Santos EC
    Parasit Vectors; 2016 Mar; 9():183. PubMed ID: 27036654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective effects of Euterpe oleracea (açai) on Leishmania (Leishmania) amazonensis and Leishmania infantum.
    Da Silva BJM; Souza-Monteiro JR; Rogez H; Crespo-López ME; Do Nascimento JLM; Silva EO
    Biomed Pharmacother; 2018 Jan; 97():1613-1621. PubMed ID: 29793323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro.
    Freitas EO; Nico D; Guan R; Meyer-Fernandes JR; Clinch K; Evans GB; Tyler PC; Schramm VL; Palatnik-de-Sousa CB
    PLoS One; 2015; 10(4):e0124183. PubMed ID: 25909893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats.
    Xiong MP; Yáñez JA; Kwon GS; Davies NM; Forrest ML
    J Pharm Sci; 2009 Apr; 98(4):1577-86. PubMed ID: 18752263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro evaluation of (-)α-bisabolol as a promising agent against Leishmania amazonensis.
    Rottini MM; Amaral AC; Ferreira JL; Silva JR; Taniwaki NN; Souza Cda S; d'Escoffier LN; Almeida-Souza F; Hardoim Dde J; Gonçalves da Costa SC; Calabrese Kda S
    Exp Parasitol; 2015 Jan; 148():66-72. PubMed ID: 25448354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HSP90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine.
    Varela-M RE; Mollinedo-Gajate C; Muro A; Mollinedo F
    Acta Trop; 2014 Mar; 131():32-6. PubMed ID: 24299925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmanicidal Activity of Isoselenocyanate Derivatives.
    Fernández-Rubio C; Larrea E; Peña Guerrero J; Sesma Herrero E; Gamboa I; Berrio C; Plano D; Amin S; Sharma AK; Nguewa PA
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30478164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.